Despite showing promising clinical efficacy in some blood cancers [1], PI3K/mTOR inhibitors lack single-agent cytotoxicity in aggressive diseases like DLBCL [45]. The gene discussed is MTOR; the disease is diffuse large B-cell lymphoma.